Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary



PDX model details

PDX ID 463.58A
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
 7
Average PDX Generation Time (days +/- SEM) 67 ± 5
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 463.58A
AR Y
PSA Y
PSMA Y
NE N
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
463.58A FANCD2 -0.742 1.196 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A IGF2R -1.414 0.750 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A KEAP1 -0.850 1.109 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A TP53 -0.822 1.132 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A FANCA -0.820 1.133 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A CDH1 -0.826 1.128 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A MGA -0.764 1.177 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A APC -1.478 0.718 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A CHD1 -1.478 0.718 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A PIK3R1 -1.478 0.718 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A SMARCAD1 -1.393 0.761 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A SMARCAD1 -1.499 0.708 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A RAF1 -0.742 1.196 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A XPO1 -0.866 1.097 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A MSH2 -0.760 1.181 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A CHD7 1.534 5.792 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A KDM6A 1.040 2.056 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A GNAS 0.539 2.906 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A SPOP 1.287 4.881 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A AKT1 0.768 3.406 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A FOXA1 0.521 2.869 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A NCOR2 0.501 2.830 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A STAB2 0.486 2.801 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A STAB2 0.565 2.960 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
463.58A MYC 1.129 4.373 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19

Clinical Information

Sample Number 463.58A
Sample Site Tumour adjacent to pancreas
Sample source Autopsy
Pathology Tumour Diagnosis None
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection Radiotherapy, zoladex, docetaxel, enzalutamide, niraparib, cabazitaxel

Patient Information

Patient Number 455/463
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) 7.8
Consent to share data

Patient Tumour Collection (Current Model)
Tumour sample ID 463.58A
Patient Age (binned in 5 year age groups) 55-59
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
463.58A GPR124 241 1.0 Missense variant '8/19 2.04E-05 26.5 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
463.58A TP53 174 1.0 Stop gained '7/11 . 37 Pathogenic Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
463.58A NCOR1 443 0.42 Missense variant '28/46 0.0007429 33 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
463.58A ZFHX3 132 0.41 Inframe insertion '10/10 . . - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
463.58A SPTA1 365 0.34 Splice acceptor variant . . 34 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500